title: The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy.
abstract: BACKGROUND
  Stage IIIB non-small cell lung cancer (NSCLC) consists of T4N2M0 and TXN3M0 NSCLC. In the present study, we aimed to evaluate the efficacy of different treatment strategies on the survival of patients with radiologically confirmed T4N2M0 NSCLC.
  
  
  METHODS
  A total of 145 patients were evaluated in three groups according to the treatment protocol: induction chemotherapy followed by chemoradiotherapy (induction group); chemoradiotherapy (CRT group), and chemoradiotherapy followed by consolidation chemotherapy (consolidation group). The groups were compared regarding survival.
  
  
  RESULTS
  The median progression-free survival (PFS) was 10.9, 10.8 and 17.1 months for the induction, CRT and consolidation groups, respectively (p = 0.021). The median overall survival (OS) was 17.6, 13.8 and 25.2 months for the induction, CRT and consolidation groups, respectively (p = 0.001).
  
  
  CONCLUSIONS
  The patients with T4N2M0 NSCLC who were treated with chemoradiotherapy followed by consolidation chemotherapy had the best outcome in terms of PFS and OS.
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.forename: Deniz
authors.initials: D
authors.lastname: Arslan
authors.forename: Şeyda
authors.initials: Ş
authors.lastname: Gündüz
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.forename: Abdullah
authors.initials: A
authors.lastname: Büyükçelik
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Benderli Cihan
authors.forename: Tuncay
authors.initials: T
authors.lastname: Aslan
authors.forename: Hakan
authors.initials: H
authors.lastname: Bozcuk
authors.forename: Hasan
authors.initials: H
authors.lastname: Şenol Coşkun
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D002755:Choice Behavior; D003131:Combined Modality Therapy / Q000379:methods; D060830:Consolidation Chemotherapy / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome